<DOC>
	<DOCNO>NCT02337543</DOCNO>
	<brief_summary>This study double blind , placebo control , ascend single multiple oral dose study conduct two part , aim determine safety tolerability single multiple oral dos NEO6860 healthy subject . Key secondary objective : assessment pharmacokinetic profile , effect food gender . The analgesic effect NEO6860 investigate use experimental capsaicin-evoked pain method . Part A comprise ascend single dose , 6 dose level . Part B comprise ascend multiple dose , 2 dose level .</brief_summary>
	<brief_title>NEO6860 , TRPV1 Antagonist , First Human Study</brief_title>
	<detailed_description>This study double blind , placebo control , ascend single multiple oral dose study conduct two part , aim determine safety tolerability single multiple oral dos NEO6860 healthy subject . Key secondary objective : assessment pharmacokinetic profile , effect food gender . The analgesic effect NEO6860 investigate use experimental capsaicin-evoked pain method . Measurement capsaicin evoke pain , secondary hyperalgesia perform baseline estimate Tmax 8 hour post dose . Part A comprise ascend single dose , sequential group study male subject , incorporate two-period crossover group investigate effect food single group female subject investigate gender effect . 56 subject study 7 group ( Groups A1 A7 ) , group consist 8 subject ( 6 subject receive NEO6860 2 receive placebo ) . Six dose level explore : 50 , 100 , 200 , 400 , 800 1 600mg . Part B comprise ascend multiple dose , sequential group study . 16 subject study 2 group ( Groups B1 B2 ) , group consist 8 subject ( 6 subject receive NEO6860 2 receive placebo ) receive 5 day therapy dose schedule determine Part A .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<criteria>Males females Any ethnic origin Between 18 55 year age Body mass index ( BMI ) 18.0 32.0 kg/m2 inclusive Body weight 50 kg 100 kg inclusive Subjects must good health , determine Medical history , Physical examination , Vital sign assessment , 12lead electrocardiogram ( ECG ) , Clinical laboratory evaluation ( congenital nonhaemolytic hyperbilirubinaemia acceptable ) Subjects give write informed consent participate study abide study restriction Male subject willing , whose partner willing , use appropriate contraception ( condom spermicidal foam/gel/film/cream/suppository ) , refrain donate sperm time first dose 3 month final dosing occasion . Subjects donate blood 3 month prior screen , plasma 7 day prior screen platelet 6 week prior screen Subjects consume 28 unit alcohol per week male consume 21 unit alcohol per week female Subjects use medication within 7 day first dose administration , unless opinion Investigator medication interfere study procedure compromise safety : Subjects clinically significant pulse rate , blood pressure temperature , opinion investigator , increase risk participate study , accordance CRU reference range screen prior first dose Subjects positive urine drug screen ( confirm repeat ) screen first admission , positive alcohol breath test result ( confirm repeat ) screen first admission Subjects abnormality 12lead ECG , opinion investigator , increase risk participate study , accordance CRU reference range screen Subjects , history , clinically significant neurological , gastrointestinal , renal , hepatic , cardiovascular , psychiatric , respiratory , metabolic , endocrine , haematological major disorder determine Investigator ALT AST &gt; 1.5 time ULN screen and/or prior first dose , confirm repeat test Subjects consider nonacceptable responder intradermal capsaicin test screening , define maximum VAS score &lt; 3 10 Subjects , opinion Investigator , participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>